ResearchBlinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
ResearchPatients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia
ResearchConsensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study
ResearchDose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia
ResearchRandomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms
ResearchImproved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL
ResearchOutcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin
ResearchIncidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplantation
ResearchOutcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement
ResearchReal-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up
ResearchOpportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy
ResearchLong-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma
ResearchThe impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
ResearchRecognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel
ResearchSanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL